Analyzing Global Cord Blood (NYSE:CORBF) and Mangoceuticals (NASDAQ:MGRX)

Global Cord Blood (NYSE:CORBFGet Free Report) and Mangoceuticals (NASDAQ:MGRXGet Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.


This table compares Global Cord Blood and Mangoceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Global Cord Blood N/A N/A N/A
Mangoceuticals -1,068.72% -864.10% -577.68%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Global Cord Blood and Mangoceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Global Cord Blood 0 0 0 0 N/A
Mangoceuticals 0 0 0 0 N/A

Earnings & Valuation

This table compares Global Cord Blood and Mangoceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Cord Blood $196.12 million N/A $79.04 million N/A N/A
Mangoceuticals $730,000.00 10.88 -$9.21 million N/A N/A

Global Cord Blood has higher revenue and earnings than Mangoceuticals.

Volatility & Risk

Global Cord Blood has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500.

Insider & Institutional Ownership

56.7% of Mangoceuticals shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by company insiders. Comparatively, 39.3% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Global Cord Blood beats Mangoceuticals on 5 of the 8 factors compared between the two stocks.

About Global Cord Blood

(Get Free Report)

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

About Mangoceuticals

(Get Free Report)

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with's FREE daily email newsletter.